GlassScriptPhysician profile
Youssef Dairi
NPI 1295875417
$13,990.16
in general payments reported to CMS, 2019-2025
29 companies · $2,827 in 2025
The $2,827 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.35 · 2021: $62.00 · 2022: $854 · 2023: $8,221 · 2024: $2,012 · 2025: $2,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,255 · Food and Beverage: $6,068 · Travel and Lodging: $738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,254.93 |
| Food and Beverage | $6,067.77 |
| Travel and Lodging | $737.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,737.89 | 2023 | Da Vinci Surgical System, Ion |
| Astrazeneca Pharmaceuticals LP | $1,304.38 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,218.34 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $585.71 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $492.53 | 2022-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $453.01 | 2022-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $380.68 | 2022-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $332.42 | 2022-2025 | Uptravi, Opsumit |
| Amgen INC. | $292.01 | 2023-2025 | Tezspire |
| Genzyme Corporation | $262.34 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $258.01 | 2023-2025 | Dupixent |
| Verona Pharma, INC. | $251.27 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $239.32 | 2022-2024 | Yupelri |
| Viatris Specialty LLC | $163.99 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $162.88 | 2022-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $154.94 | 2024-2025 | |
| Baxter Healthcare | $108.07 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Mallinckrodt Hospital Products INC. | $103.21 | 2022-2025 | Acthar |
| Axsome Therapeutics, INC. | $96.46 | 2023-2024 | Sunosi |
| Vifor Pharma, INC. | $91.47 | 2024-2025 | Zemaira |
| Philips North America LLC | $80.62 | 2023-2024 | (Ak6) Vest Therapy |
| Idorsia Pharmaceuticals US INC | $53.91 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $43.91 | 2023-2025 | Inspire |
| Inogen, INC. | $38.58 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Mayne Pharma Commercial LLC | $19.40 | 2022 | |
| Merck Sharp & Dohme LLC | $19.04 | 2023 | Belsomra |
| Pulmonx Corporation | $16.86 | 2021 | |
| Electromed, INC. | $15.06 | 2025 | Smartvest |
| Liquidia Technologies, INC. | $13.85 | 2025 | Yutrepia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Dairi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.